Abstract
Abstract Disclosure: S.P. Agramonte Villar: None. C.R. Gil Vega: None. J.M. Reynoso Ortiz: None. L.R. Sosa Pinedo: None. R.A. Vasquez Morel: None. C.M. Polanco Santos: None. V.T. San Martin: None. Background: Obesity is a major risk factor for the development and progression of type 2 diabetes mellitus (T2DM). Among the modifiable factors that can promote weight gain is the use of obesogenic medications (OM). The prevalence of the use of OM in patients with T2DM in the Dominican Republic (DR) is unknown. Objective: This study aimed to evaluate the use of OM among patients with T2DM in the DR. Methods: Cross-sectional study based on patient surveys and anthropometric measurements obtained in an outpatient primary care clinic in Santo Domingo, DR between October 2022 and November 2022. Patients aged ≥18 years with a known diagnosis of T2DM were included. Weight status was categorized according to body mass index (BMI). OM were defined according to the study by Hales et al1. Results: A total of 220 patients were surveyed and analyzed. Overall, 57.7% (127/220) of the patients reported a current use of one or more OM; 50.0% (110/220) were using one OM, 6.4% (14/220) were using two OM, and 1.3% (3/220) were using three OM. Among the patients using at least one OM, 45.7% (58/127) had overweight (BMI 25.0-29.9 kg/m2) and 40.9% (52/127) had obesity (BMI >30 kg/m2). The most frequently used antidiabetes OM was insulin [any type] (n=83), followed by glyburide (n=17) and glimepiride (n=13). The most commonly used non-antidiabetes OM was metoprolol (n=8), followed by atenolol (n=6) and pregabalin (n=6). Conclusion: More than half of the patients with T2DM were using at least one OM. The use of OM can contribute to weight gain and may hinder weight loss efforts in these patients, thus potentially negatively impacting the management of their underlying chronic disease. Reference: 1. Hales CM et al. Use of prescription medications associated with weight gain among US adults, 1999-2018: A nationally representative survey. Obesity (Silver Spring). 2022;30:229-239. Presentation: Friday, June 16, 2023
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
